| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Stroke Program, Department of Neurology, University of Texas at Houston, and Stroke Program (Dr. Morgenstern), University of Michigan Health System, Ann Arbor; Departments of Internal Medicine (Drs. Viscoli and Kernan, and R.I. Horwitz), Neurology (Dr. Brass), and Epidemiology and Public Health (Dr. Brass and R.I. Horwitz), Yale University School of Medicine, New Haven, CT; Department of Neurology (Dr. Broderick), University of Cincinnati, OH; Department of Neurology (Dr. Feldmann and Wilterdink), Brown University School of Medicine, Providence, RI; and Department of Neurology (Dr. Brott), Mayo Clinic, Jacksonville, FL.
Address correspondence and reprint requests to Dr. Lewis B. Morgenstern, Stroke Program, Department of Neurology, University of Michigan Health System, TC 1920/0316, Ann Arbor, MI 48109; e-mail: lmorgens{at}umich.edu
This case-control study examined the association between Ephedra use and risk for hemorrhagic stroke. For use of Ephedra at any dose during the 3 days before the stroke, the adjusted OR was 1.00 (95% CI 0.32 to 3.11). For daily doses of 
32 mg/day, the OR was 0.13 (95% CI 0.01 to 1.54), and for >32 mg/day, the OR was 3.59 (95% CI 0.70 to 18.35). Ephedra is not associated with increased risk for hemorrhagic stroke, except possibly at higher doses.
This article has been cited by other articles:
|
|
 |
|
  J. Hallas, L. Bjerrum, H. Stovring, and M. Andersen Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study Am. J. Epidemiol., October 15, 2008; 168(8): 966 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Roach, M. R. Golomb, R. Adams, J. Biller, S. Daniels, G. deVeber, D. Ferriero, B. V. Jones, F. J. Kirkham, R. M. Scott, et al. Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young Stroke, September 1, 2008; 39(9): 2644 - 2691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Westover, S. McBride, and R. W. Haley Stroke in Young Adults Who Abuse Amphetamines or Cocaine: A Population-Based Study of Hospitalized Patients Arch Gen Psychiatry, April 1, 2007; 64(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Grippo, B. Hamilton, R. Hannigan, and B. J. Gurley Metal content of ephedra-containing dietary supplements and select botanicals Am. J. Health Syst. Pharm., April 1, 2006; 63(7): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Dennehy, C. Tsourounis, and A. J. Horn Dietary supplement-related adverse events reported to the California Poison Control System Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1476 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smolinske Herbal Product Contamination and Toxicity Journal of Pharmacy Practice, June 1, 2005; 18(3): 188 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 S. B. Karch, W.N. Kernan, L.M. Brass, C.M. Viscoli, J. P. Broderick, T. Brott, E. Feldmann, J.L. Wilterdink, and L.M. Morgenstern Use of Ephedra-containing products and risk for hemorrhagic stroke Neurology, September 9, 2003; 61(5): 724 - 725. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Sirven, J. F. Drazkowski, R. S. Zimmerman, J. J. Bortz, D. L. Shulman, and M. Macleish Complementary/alternative medicine for epilepsy in Arizona Neurology, August 26, 2003; 61(4): 576 - 577. [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Shekelle, M. L. Hardy, S. C. Morton, M. Maglione, W. A. Mojica, M. J. Suttorp, S. L. Rhodes, L. Jungvig, and J. Gagne Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance: A Meta-analysis JAMA, March 26, 2003; 289(12): 1537 - 1545. [Abstract] [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
